AstraZeneca

Showing 15 posts of 785 posts found.

AstraZenecaโ€™s Soliris given EU CHMP recommendation for marketing authorisation

June 26, 2023
Medical Communications AstraZeneca, CHMP, EMA, Immunology, soliris

UK-based biopharmaceutical company AstraZeneca has announced that the European Medicines Agencyโ€™s (EMAโ€™s) Committee for Medicinal Products for Human Use (CHMP) …

cancer_cells_from_the_breast_cancer_now_tissue_bank_cell_programme

AstraZenecaโ€™s breast cancer drug given Priority Review by FDA

June 13, 2023
Business Services AstraZeneca, FDA, Oncology, breast cancer

UK-based pharmaceutical company AstraZeneca has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application …

AstraZeneca and MSDโ€™s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

June 9, 2023
Research and Development AstraZeneca, Cancer, MSD, NICE, Oncology, lynparza, pharma

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) posted a positive recommendation …

AstraZenecaโ€™s phase 4 trial stopped early after reaching pre-specified criteria

June 5, 2023
Research and Development ANNEXA-I, Andexxa, AstraZeneca, Neurology, clinical trial

AstraZeneca has announced that its post-marketing phase 4 ANNEXA-I trial has been stopped early after reaching its pre-specified stopping criteria. …

robina-weermeijer-ihfopazzjhm-unsplash_5

AstraZenecaโ€™s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD

May 30, 2023
Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris

AstraZeneca has announced that Ultomiris (ravulizumab) has been approved in Japan as a long-acting C5 complement inhibitor for the prevention …

national-cancer-institute-kmvohcb-w5g-unsplash_1

AstraZeneca shares oncology data at ASCO 2023

May 25, 2023
Medical Communications ASCO, AstraZeneca, Cancer, Oncology, oncology

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting on …

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

May 17, 2023
Research and Development AstraZeneca, Cancer, Oncology, Tagrisso, chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso (osimertinib), in combination with chemotherapy, …

LaNova Medicines and AstraZeneca sign global exclusive license agreement for preclinical ADC

May 15, 2023
Research and Development ADC, AstraZeneca, LaNova Medicines, License Agreement, Oncology

Chinese biotechnology company LaNova Medicines and UK-based pharma company AstraZeneca have announced that they have signed a global exclusive license …

AstraZenecaโ€™s Ultomiris approved in EU for adults firm NMOSD

May 11, 2023
Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris, neurology

AstraZeneca has announced the approval of Ultomiris (ravulizumab) in the European Union (EU) for the treatment of adult patients with …

AstraZenecaโ€™s Farxiga approved to reduce risk of cardiovascular death

May 9, 2023
Medical Communications AstraZeneca, Cardiology, FDA, cvd, farxiga, heart failure

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Farxiga to reduce the risk of cardiovascular …

pm_society

AstraZeneca, Klarify, and Novartis Gene Therapies top Digital Awards leaderboard

September 20, 2021
Sales and Marketing AstraZeneca, Klarify, Novartis, PM Society Awards, havas life medicom

Pharmaceutical companies AstraZeneca, Klarify, and Novartis Gene Therapies all received two gold awards at the 12th PM Society Digital Awards …

Health Canada announce first full approval for Moderna COVID-19 vaccine

September 17, 2021
Medical Communications AstraZeneca, BioNTech, Health Canada, Moderna, Pfizer, mrna

Canada has become the first country in the world to grant full approval to the Moderna vaccine, alongside confirmation for …

xxx

RNA breakthrough: Fluorescence used to track molecule movement

June 30, 2021
Research and Development AstraZeneca, RNA, mrna

Researchers at Chalmers University of Technology in Sweden have announced a breakthrough in the labelling method of messenger RNA (mRNA) …

astrazeneca_plaque

Australia pauses AstraZeneca vaccine for people under 60

June 18, 2021
Medical Communications AstraZeneca, Australia, COVID-19, Vaccine

Australia will now only recommend that people over 60 receive the AstraZeneca vaccine due to the rare occurrence of post-jab …

az

AstraZeneca antibody fails to prevent COVID in exposed patients

June 15, 2021
Manufacturing and Production AstraZeneca, COVID-19, Primary Endpoint, antibody, trial

AstraZeneca has failed to reach the primary endpoint in their Storm Chaser trial, assessing the safety and efficacy of AZD7442, …

The Gateway to Local Adoption Series

Latest content